Breast cancer Archives

Combined hormone therapy makes breast cancer detection difficult

LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies; may reduce effectiveness of both methods for detecting cancer. – Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Genentech’s Avastin with chemotherapy approved for advanced breast cancer

FDA grants accelerated approval of Avastin in combination with Paclitaxel Chemotherapy for first-line treatment of advanced HER2-negative breast cancer. – Genentech, Inc. (NYSE: DNA) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Avastin (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.

Uninsured diagnosed with an advanced stage cancer

Uninsured or Medicaid-insured patients are far more likely to be diagnosed with an advanced stage cancer than those with private insurance, according to a new American Cancer Society study of 3.5 million cancer patients with 12 of the most common cancer types. – A new American Cancer Society study of twelve types of cancer among more than 3.5 million cancer patients finds uninsured patients were significantly more likely to present with advanced stage cancer compared to patients with private insurance.

Excess bodyweight raises cancers risk

Excess bodyweight, expressed as increased body-mass index (BMI), is associated with the risk of some common adult cancers. – Increased body mass index (BMI) increases the risk of common and less common cancers, and the level of risk can vary between the sexes and different ethnic groups depending on the type of cancer.

Zydus Cadila introduces Nudoxa cancer drug

Zydus Cadila has introduced Nudoxa for the treatment of various cancers. One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach in cancer therapy. – Zydus Cadila has introduced an NDDS product ‘Nudoxa’ for the treatment of various cancers. One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach in cancer therapy.

DCIS patients overestimate breast cancer risks

Many women diagnosed with ductal carcinoma in situ (DCIS) have inaccurate perceptions of their breast cancer risks, according to a study published online February 12 in the Journal of the National Cancer Institute. – Many women with newly diagnosed DCIS have inaccurate perceptions of the breast cancer risks that they face, and anxiety is particularly associated with these inaccurate perceptions.

Avastin found effective in advanced breast cancer patients

Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer – Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin? (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.

21% errors in pathology reports in Miramichi Hospital, New Brunswick

21% errors in pathology reports by previous unidentified pathologist in Miramichi Hospital, New Brunswick, Canada, reported by Dr. Rosemary Henderson, pathologist. – An additional review of pathology reports in Miramichi Hospital, New Brunswick is completed by Dr. Rosemary Henderson, pathologist. This review included 227 cases of prostate and breast cancer biopsies from 2004-2005. The results indicated that 18 percent of the cases had incomplete results and three percent of the cases were misdiagnosed.

Breast cancer sufferers demand answers from PHARMAC, New Zealand

Herceptin Heroines are back in the High Court today to continue their case against drug funding agency PHARMAC, New Zealand. – 8 cancer survivors are in the New Zealand High Court to fight their case against drug funding agency PHARMAC. The women are challenging PHARMAC’s decision not to fund 12 months of Herceptin treatment for NZ women with HER2 positive breast cancer.

1 in 20 breast cancer web pages features inaccuracies

Review of online breast cancer information encourages healthy skepticism for consumers; Quality criteria does not determine accuracy of web site. Web site quality criteria failed to detect online health information errors during a study by UT researchers Elmer Bernstam, M.D., and his wife, Funda Meric-Bernstam, M.D. – In an extended analysis of Web pages dedicated to disseminating breast cancer information, researchers at two University of Texas institutions in Houston have determined that while most breast cancer data found online was accurate, one in 20 breast cancer Web pages featured inaccuracies and sites displaying complementary and alternative medicine were 15 times more likely to contain false or misleading health information.

Ban use of bisphenol A in baby bottles

Environmental health groups call for immediate moratorium on bisphenol A in baby bottles, food and beverage containers. Baby bottles leach toxic chemical, according to new U.S. and Canadian Study. – Dozens of state and national environmental health organizations in the U.S. and Canada are calling for an immediate moratorium on the use of bisphenol A (BPA) in baby bottles and other food and beverage containers, based on the results of a new study that demonstrates the toxic chemical BPA leaches from popular plastic baby bottles when heated.

Oral contraceptive pills can protect against ovarian cancer

The longer a woman uses the oral contraceptive pill, the lower her risk of getting ovarian cancer later in life. Oral contraceptives give substantial long-term protection against ovarian cancer. – Use of oral contraceptives during a woman’s life-time gives substantial long-term protection against ovarian cancer and the longer they are used, the greater the reduction in risk. These are the conclusions of authors of an Article in this week’s edition of The Lancet – a medical journal in the United Kingdom.